Literature DB >> 3924670

Does constant infusion of gonadotropin-releasing hormone agonist lead to greater suppression of gonadal function in man than its intermittent administration?

S Bhasin, B Steiner, R Swerdloff.   

Abstract

Constant infusion of gonadotropin-releasing hormone agonist (GnRH-A) in the rhesus monkey leads to far greater suppression of spermatogenesis than its intermittent administration. To assess whether administration of GnRH-A by constant subcutaneous infusion will also lead to greater inhibition of gonadal function, we administered either 20 or 200 micrograms of D(Nal2)6GnRH (GnRH-A) to two groups of normal male volunteers, either by a single daily injection or constant subcutaneous infusion through a portable infusion pump, for 28 days. Basal and integrated luteinizing hormone (LH), follicle-stimulating hormone, and testosterone (T) responses were not significantly different between the two methods of GnRH-A administration at either the 20- or 200-microgram dose, even though subjects in the constant infusion group showed more consistent inhibition of basal and 24-hour integrated T concentrations. Significant decline in serum T in both groups occurred in the face of little or no decline in serum LH. It is concluded that the effects of constant infusion of GnRH-A in man are not as striking as those reported in the rhesus monkey and that the antigonadal effects of GnRH-A in man are complex and cannot be explained on the basis of down-regulation of pituitary gonadotropin secretion alone--additional mechanisms may be operative.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924670     DOI: 10.1016/s0015-0282(16)48684-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

Review 1.  Hormonal approaches to male contraception.

Authors:  Christina Wang; Ronald S Swerdloff
Journal:  Curr Opin Urol       Date:  2010-11       Impact factor: 2.309

2.  Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men.

Authors:  G Valenti; L Denti; A Banchini; G Ceresini; G P Ceda; W C Westel; A Negro-Vilar
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

Review 3.  Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.